We are live on ! Find out more
AG

Artal Group Portfolio holdings

AUM $1.01B
1-Year Est. Return 29.84%
This Fund
S&P 500
This Quarter Est. Return
+17.01%
1 Year Est. Return
+29.84%
3 Year Est. Return
+144%
5 Year Est. Return
+76.57%
10 Year Est. Return
+1,417.6%
AUM
$5.66B
AUM Growth
+$1B
Cap. Flow
+$784M
Cap. Flow %
13.85%
Top 10 Hldgs %
43.17%
Holding
164
New
34
Increased
29
Reduced
25
Closed
18

Top Buys

Rank Stock Value
1
INTC icon
Intel
INTC
+$47.7M
2
ARGX icon
argenx
ARGX
+$47.4M
3
MRTX
Mirati Therapeutics, Inc. Common Stock
MRTX
+$44.5M
4
IMA
ImageneBio Inc
IMA
+$44.2M
5
ACHL
Achilles Therapeutics
ACHL
+$37.3M

Top Sells

Rank Stock Value
1
GDS icon
GDS Holdings
GDS
+$89.7M
2
Z icon
Zillow
Z
+$66.8M
3
ONC
BeOne Medicines Ltd
ONC
+$49.7M
4
BABA icon
Alibaba
BABA
+$46.5M
5
QURE icon
uniQure
QURE
+$25.3M

Sector Composition

Rank Sector Weight
1 Healthcare 68.71%
2 Consumer Discretionary 8.71%
3 Technology 1.72%
4 Communication Services 0.79%
5 Real Estate 0.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGEN
76
Agenus
AGEN
$276M
$16.3M 0.29%
305,700
-45,855
-13% -$3.31M
BBIO icon
77
BridgeBio Pharma
BBIO
$16.4B
$15.4M 0.27%
250,000
-50,000
-17% -$3.27M
KWEB icon
78
CALL
KraneShares CSI China Internet ETF
KWEB
$5.5B
$15.3M 0.27%
+200,000
New +$17.5M
NBTX
79
Nanobiotix
NBTX
$1.92B
$15M 0.27%
1,000,000
– –
ADAG
80
Adagene
ADAG
$246M
$14.4M 0.25%
+800,000
New +$18.2M
ZYME icon
81
Zymeworks
ZYME
$1.62B
$14.2M 0.25%
450,000
+100,000
+29% +$4.06M
RLAY icon
82
Relay Therapeutics
RLAY
$4B
$13.8M 0.24%
400,000
– –
SANA icon
83
Sana Biotechnology
SANA
$882M
$13.4M 0.24%
+400,000
New +$13M
YI
84
111 Inc
YI
$31.3M
$13.3M 0.24%
96,635
-3,365
-3% -$489K
ORTX
85
DELISTED
Orchard Therapeutics plc American Depositary Shares
ORTX
$13.1M 0.23%
180,386
+145,236
+413% +$10.3M
AUPH icon
86
Aurinia Pharmaceuticals
AUPH
$1.95B
$13M 0.23%
1,000,000
– –
Z icon
87
Zillow
Z
$7.78B
$13M 0.23%
100,000
-450,000
-82% -$66.8M
IOVA icon
88
Iovance Biotherapeutics
IOVA
$2.04B
$12.7M 0.22%
400,000
– –
SLDB icon
89
Solid Biosciences
SLDB
$792M
$12.4M 0.22%
+150,000
New +$16.6M
MRNS
90
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$12.4M 0.22%
800,000
+500,000
+167% +$7.23M
YMAB
91
DELISTED
Y-mAbs Therapeutics
YMAB
$12.1M 0.21%
400,000
+114,972
+40% +$4.71M
DSGN icon
92
Design Therapeutics
DSGN
$751M
$12M 0.21%
+400,000
New +$13.5M
BMRN icon
93
CALL
BioMarin Pharmaceuticals
BMRN
$11.9B
$11.3M 0.2%
150,000
– –
TIL icon
94
Instil Bio
TIL
$49M
$11.3M 0.2%
+22,500
New +$11.5M
TME icon
95
Tencent Music
TME
$15.9B
$11.3M 0.2%
+550,000
New +$14M
IMUX icon
96
Immunic
IMUX
$178M
$11.2M 0.2%
70,000
– –
EVLO
97
DELISTED
Evelo Biosciences, Inc. Common Stock
EVLO
$10.7M 0.19%
50,000
+15,000
+43% +$4.15M
OVID icon
98
Ovid Therapeutics
OVID
$427M
$10.1M 0.18%
2,500,000
– –
TCOM icon
99
Trip.com Group
TCOM
$29B
$9.91M 0.18%
250,000
-250,000
-50% -$9.26M
KYMR icon
100
Kymera Therapeutics
KYMR
$8.66B
$9.71M 0.17%
250,000
– –
2 3
4
5 6

Similar funds

BCM
Bronte Capital Management Bondi Junction, Australia $1.01B AUM 47.99% 1-Year Est. Return
GA
GRS Advisors Chicago, Illinois $1.01B AUM 13.12% 1-Year Est. Return
EPAM
Euro Pacific Asset Management Dorado, Puerto Rico $1.01B AUM 79.26% 1-Year Est. Return
WA
Wealth Alliance Mellville, New York $1.01B AUM 19.71% 1-Year Est. Return
CT
Coastline Trust Providence, Rhode Island $1.01B AUM 22.57% 1-Year Est. Return
AH
Allen Holding New York $1.01B AUM 27.61% 1-Year Est. Return
PIM
Provident Investment Management Novi, Michigan $1.01B AUM 9.4% 1-Year Est. Return
MAM
Melqart Asset Management London, United Kingdom $1.01B AUM 84.85% 1-Year Est. Return

Artal Group's Q1 2021 Portfolio in Review

As of Q1 2021, Artal Group held 164 positions worth $5.66B, up 21% from $4.66B the previous quarter. Its ten largest holdings account for 43% of the portfolio.

Artal Group deployed $784M of net new capital in Q1 2021, opening 34 new positions and adding to 29 existing holdings. Its largest new stake was Intel: 800,000 shares worth $51.2M.

By sector, the portfolio is most concentrated in Healthcare at 69% of assets, down from 77% a quarter earlier, followed by Consumer Discretionary and Technology.

On the sell side, the largest reduction was GDS Holdings, an estimated $89.7M trimmed.

  • Artal Group's largest Q1 2021 buy was Intel: 800,000 shares worth $51.2M.
  • Artal Group added most to argenx in Q1 2021, an estimated $47.4M increase.
  • Artal Group's biggest Q1 2021 reduction was GDS Holdings, cutting an estimated $89.7M.
  • Artal Group fully exited Alibaba in Q1 2021, selling an estimated $46.5M.
  • Artal Group's ten largest holdings make up 43% of its $5.66B portfolio in Q1 2021.
  • Artal Group opened 34 new positions and closed 18 in Q1 2021.
  • Artal Group's portfolio value rose 21% quarter-over-quarter to $5.66B.

Based on Artal Group's 13F filing for Q1 2021, filed 14 May 2021.